Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 18/20 | 0.53 |
| ▸ | JAK2 | O60674 | 15/20 | 0.53 |
| ▸ | TYK2 | P29597 | 8/20 | 0.53 |
| ▸ | JAK3 | P52333 | 7/20 | 0.52 |
| ▸ | IKBKB | O14920 | 1/20 | 0.52 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21757166 | 0.92 | JAK1 (0.56) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL23424216 | 0.92 | JAK1 (0.54) | JAK1JAK2TYK2JAK3IKBKB | |
| SCHEMBL23424188 | 0.86 | JAK1 (0.57) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL23424176 | 0.86 | JAK1 (0.49) | JAK1JAK2TYK2JAK3IKBKB | |
| SCHEMBL21242957 | 0.83 | JAK1 (0.68) | JAK1JAK2TYK2JAK3IKBKB | |
| SCHEMBL21242708 | 0.81 | JAK1 (0.76) | JAK1JAK2TYK2JAK3IKBKB | |
| SCHEMBL23424211 | 0.80 | JAK1 (0.55) | JAK1JAK2TYK2JAK3IKBKB | |
| SCHEMBL23424214 | 0.79 | JAK2 (0.72) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL21757098 | 0.79 | JAK2 (0.56) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL3594593 | 0.76 | JAK2 (0.75) | JAK1JAK2TYK2JAK3IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021159372-A1 | USE OF JAK INHIBITORS IN PREPARATION OF DRUGS FOR TREATING JAK KINASE-RELATED DISEASES | 珠海联邦制药股份有限公司 | 2021-08-19 | — | — | WO | disclosed |
| US-20210155621-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUND AS JAK INHIBITOR AND USE THEREOF | ZHUHAI UNITED LABORATORIES CO., LTD. (CN) | 2021-05-27 | — | — | US | disclosed |
| WO-2020038457-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUND AS JAK INHIBITOR AND APPLICATION THEREOF | 珠海联邦制药股份有限公司 | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155621-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUND AS JAK INHIBITOR AND USE THEREOF | JAK1, JAK2, TYK2 | JAK1 1/4885JAK2 2/4885TYK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.